HB3749, the Health and Endocrine Research on personal care products for women Act or “HER Act,” would direct the Secretary of Health and Human Services, acting through the National Institute of Environmental Health Sciences, to award grants for research on how personal care products containing endocrine-disrupting chemicals affect the female reproductive system and related reproductive toxicity concerns. The bill also requires HHS to produce public reports every five years summarizing research findings, disparities in access to safer products, and possible legislative or administrative strategies to expand FDA oversight of harmful ingredients in personal care products.
In addition to federal research grants, the bill authorizes grants to states, territories, and Indian tribes or tribal organizations for investigations and public education campaigns about the health impacts of endocrine-disrupting chemicals in personal care products and the use of safer alternatives. The bill defines endocrine-disrupting chemicals broadly as substances that mimic, block, or interfere with hormones, and defines personal care products as cosmetics intended for hygiene, grooming, or other personal care.
Impact
The bill would not itself ban or regulate specific ingredients, but it would create a federal grant and reporting framework within HHS and NIEHS focused on women’s reproductive health and cosmetic safety. It could influence future FDA policy or legislation by generating research, identifying harmful and safer products, and recommending ways to expand FDA authority over endocrine-disrupting ingredients in cosmetics and personal care products. It would also make states, territories, and tribal governments eligible for federal funding to conduct investigations and public awareness efforts.
Sentiment
Based on the bill text and the absence of recorded committee debate or votes, the available context suggests the measure is framed as a public health and consumer safety initiative rather than a controversial regulatory overhaul. Its emphasis on women’s reproductive health, safer products, and public education indicates a generally supportive policy posture among the sponsors. No formal vote history or transcript record is available here to show broader bipartisan or partisan reaction.
Contention
The main policy tension in the bill is its call for evidence-based or evidence-informed strategies to increase FDA’s domain over personal care product ingredients, which could be viewed by some as a step toward stronger federal regulation of cosmetics. Potential points of contention include the scope of FDA authority, how endocrine-disrupting chemicals are identified, and whether the bill’s reporting could lead to future restrictions on industry products. Another possible issue is the breadth of the definitions and the inclusion of tribal entities and territories in the grant program, though no specific objections are recorded in the available materials.